ARP Global Capital Ltd has established a new position in Eli Lilly and Company, purchasing 15,840 shares of the pharmaceutical giant during the fourth quarter. This acquisition, valued at approximately $17,023,000, positions Eli Lilly as the sixth largest investment in ARP Global Capital’s portfolio, accounting for 5.1% of its total holdings.
The move by ARP Global Capital reflects a broader trend, as several institutional investors have also recently adjusted their stakes in Eli Lilly. For example, 10Elms LLP increased its investment by 33.3%, now holding 40 shares valued at $31,000 after acquiring an additional ten shares. Similarly, M.E. Allison & CO. Inc. raised its holdings by 0.7%, bringing its total to 1,477 shares worth $1,587,000.
Other notable changes include Tanager Wealth Management LLP, which boosted its position in Eli Lilly by 2.6%, and Morey & Quinn Wealth Partners LLC, which increased its holdings by 1.5%. Collectively, institutional investors now own 82.53% of Eli Lilly’s stock, indicating robust confidence in the company’s future.
Eli Lilly’s Financial Performance and Analyst Ratings
Eli Lilly recently reported its quarterly earnings on February 4, 2024, showcasing strong financial results that exceeded analysts’ expectations. The company posted earnings of $7.54 per share, surpassing the consensus estimate of $7.48 by $0.06. With a net margin of 31.66% and a return on equity of 102.94%, Eli Lilly demonstrated significant profitability. The firm achieved revenue of $19.29 billion for the quarter, far exceeding the predicted $17.85 billion and reflecting a 42.6% increase year-over-year.
Looking ahead, Eli Lilly has set its fiscal year 2026 guidance at 33.500-35.000 EPS, while analysts expect an average of 23.48 EPS for the current fiscal year.
Analysts Optimistic About Eli Lilly’s Future
A number of research firms have issued new ratings for Eli Lilly. Barclays initiated coverage with an “overweight” rating and a price target of $1,350.00. Meanwhile, UBS Group reiterated a “buy” rating, and Guggenheim raised its price target from $1,161.00 to $1,168.00. Sanford C. Bernstein also reaffirmed an “outperform” rating on the stock.
Currently, the consensus among analysts is a “Moderate Buy,” with two analysts rating the stock as a Strong Buy, twenty-three as Buy, and five as Hold. According to MarketBeat.com, the average price target for Eli Lilly stands at $1,229.59.
Overall, Eli Lilly and Company, founded in 1876 and headquartered in Indianapolis, Indiana, remains a key player in the pharmaceutical industry. The company’s focus on research, development, and commercialization of a diverse range of medicines continues to attract significant investment and positive analyst attention.
